The Deafening Noise of Exploitation in Technology

Once again, the relentless pursuit of AI-powered miracles cloaks corporate greed in a shimmering veneer of progress. Beneath the headlines of biotechnology revolution lies a chilling narrative: the unchecked race to profit, while true innovation to serve humanity drowns in a sea of shareholder greed.

AbbVie: Profits Over Purpose

AbbVie revels in its ruthless monopoly over the pharmaceutical world, parading “Skyrizi” and “Rinvoq” as breakthroughs after squeezing every ounce of profit out of “Humira.” What do they care about the millions still clamoring for affordable medication? Meanwhile, their so-called AI-powered “ARCH” system promises efficiency—but let’s not kid ourselves about whose interests it serves. Cutting drug development times? Sure, if it paves the way for accelerated price hikes on their “pipeline of profit.”

Gilead Sciences: The Faux Innovator

For Gilead, the script is simple: milk the success of antiviral treatments while shouting into the void about diversification. Their expanded AI partnerships may seem forward-thinking, but it’s a calculated smokescreen. Behind every bold headline lies a cold, profit-hungry machine with one goal: dominating markets, not saving lives. Their venture with Terray? Another power play disguised in the glow of “collaboration.”

Moderna’s Mirage of Promise

Moderna, the “darling” of mRNA tech, paints itself as a phoenix rising from the ashes of dwindling COVID-19 revenue. But let’s cut through the charade. Every call for recovery reeks of desperation. Ten new product approvals in three years? That’s not ambition—it’s an exercise in PR spin. If Moderna’s AI dreams are supposed to inspire confidence, its bleeding investors demand receipts—not just lofty narratives of innovation.

The Unyielding Hunger for Control

This isn’t biotechnology. It’s a crusade of unchecked power, veiled in scientific language. AbbVie, Gilead, and Moderna may wave their AI flags high, but ask yourselves: who benefits in the end? The answer lies not in advancing global welfare but in feeding the insatiable appetite of corporate empires. Humanity becomes merely collateral damage in their obsessive race to dominate markets.

Where Does the Line Break?

The biotech world spins a compelling tale of AI innovation, but let’s stop applauding their hollow victories. In the name of progress, should citizens accept exploitation as the cost of innovation? Maybe it’s time for these corporations to answer not just to their shareholders but to those still waiting for accessible breakthroughs that won’t rob them blind.

Source: finance.yahoo.com/news/3-top-ai-powered-biotech-144500528.html